The first patient to be treated with Alzheimer’s disease , in the German city of Frankfurt in 1901, was a 51-year-old woman named Auguste.

Despite this, and although Alzheimer’s is twice as prevalent in women, more than 120 years later research remains largely focused on men.

Among studies that include men and women, only 42 per cent conduct analysis of the differences between the sexes.

The reason often given for women’s exclusion in research is their increased hormonal variability. Now, it is precisely this hormonal variability that researchers want to examine.

A new $US50 million global program ($77 million) has the goal of halving the lifetime risk of Alzheimer’s disease in women through funding research into sex-specific biomarkers and interventions.

One of the 16 recipient

See Full Page